Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Sandip Patel, MBBS, Tiffany George, MD, Tzu-Fei Wang, MD MPH, Sherry Mori Vogt, Pharm D, Edmund Folefac, MD, Ming Yin, MD

Blood (2019) 134 (Supplement_1): 3681.

https://doi.org/10.1182/blood-2019-130465

Published: 2019

Journal Articles

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Torsten Kessler, MD, Steffen Koschmieder, MD, Christoph Schliemann, MD, Martina Crysandt, Jan-Henrik Mikesch, MD, Matthias Stelljes, MD, Linus Angenendt, Georg Lenz, Anna Kirsch, Kerstin Vehring, Hartmann Wolfgang, Eva Wardelmann, Eike Bormann, Joachim Gerss, Tim H. Brümmendorf, MD, Carsten Mueller-Tidow, Wolfgang E. Berdel, MD

Blood (2018) 132 (Supplement 1): 5176.

https://doi.org/10.1182/blood-2018-99-118095

Published: 2018

Journal Articles

Preclinical Evidence That Trametinib Enhances the Response to Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia

Joaquín Martínez-López, MD PhD, María Linares, Maria Luz Morales, Alicia Arenas, Ivana Zagorac, Rosa M. Ayala, MD PhD, Nerea Castro, Inmaculada Rapado, PhD, Miguel Quintela-Fandino

Blood (2016) 128 (22): 1581.

https://doi.org/10.1182/blood.V128.22.1581.1581

Published: 2016

Journal Articles

The Impact of Chemotherapeutic Agents on Signaling and Epigenetics in Vascular Endothelial Cells

Srila Gopal, MD, Amanda Creech, Adam Officer, Shawn Egri, Desiree Davison, Jacob D Jaffe, PhD, Iris Z Jaffe, MD PhD

Blood (2016) 128 (22): 1353.

https://doi.org/10.1182/blood.V128.22.1353.1353

Published: 2016

Journal Articles

Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia Relapsing after Allogeneic Stem Cell Transplantation

Jessica I Hoell, MD, Sebastian Ginzel, MSc, Cornelia Eckert, PhD, Michael Gombert, PhD, Ute Fischer, PhD, Martin Stanulla, MD, Martin Schrappe, MD PhD, Udo zur Stadt, PhD, Peter Bader, MD, Brigitte Strahm, MD, Julia Alten, Anja Moericke, MD, Gabriele Escherich, MD, Arend Stackelberg, MD, Christina Peters, MD, Arndt Borkhardt, MD, Roland Meisel, MD

Blood (2016) 128 (22): 601.

https://doi.org/10.1182/blood.V128.22.601.601

Published: 2016

Journal Articles

Identification of Targeted Therapies for Rare Adult Mature T-Cell Leukemia Using Functional Ex Vivo Screening of Primary Patient Samples

Uma Borate, MD, Brianna A. Norris, Pierrette Lo, MS, Cristina E. Tognon, Brian Junio, Jeffrey W. Tyner, Brian J. Druker, MD

Blood (2016) 128 (22): 4720.

https://doi.org/10.1182/blood.V128.22.4720.4720

Published: 2016

Journal Articles

Chemosensitizing Leukemia By Targeting the Leukemia Microenvironment with Vascular Disrupting Combretastatins

Raphael C Bosse, BS, Briana Wasserstrom, Elizabeth Wise, BS, Amy Meacham, MS, Christopher R. Cogle, MD

Blood (2014) 124 (21): 2315.

https://doi.org/10.1182/blood.V124.21.2315.2315

Published: 2014

Journal Articles

Development of a Clinically Relevant in Vitro Drug Screening Platform for Chemo-Refractory AML Patients

Stephen Sze Yuen Lam, Chae Yin Cher, Nelson Ka Lam Ng, Eric SK Ho, Cheuk Him Man, PhD, Howard CH Chow, Connie J Eaves, Alice MS Cheung, PhD, Anskar Y.H. Leung, MD

Blood (2014) 124 (21): 3624.

https://doi.org/10.1182/blood.V124.21.3624.3624

Published: 2014

Journal Articles

Activities Of Commonly Used Tyrosine Kinase Inhibitors Against Wild-Type C-KIT and Potential Impact On Normal Hematopoiesis

Allison Galanis, Mark Levis, MD, PhD

Blood (2013) 122 (21): 3846.

https://doi.org/10.1182/blood.V122.21.3846.3846

Published: 2013

Journal Articles

Differential Activity of Pazopanib and Imatinib Against PDGFRA-Related MPN and AML

Steffen Koschmieder, MD, Mirle Schemionek, PhD, Christian Elling, PhD, Utz Krug, MD, Torsten Kessler, MD, Wolfgang E. Berdel, Carsten Müller-Tidow, MD

Blood (2011) 118 (21): 5153.

https://doi.org/10.1182/blood.V118.21.5153.5153

Published: 2011

Journal Articles

The Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Possess Strong Inhibitory Effect on Tumor Growth In a CLL-Like Xenograft Mouse Model

Julian Paesler, Iris Gehrke, Regina Razavi, Simon Jonas Poll-Wolbeck, Michael Hallek, M.D., Karl-Anton Kreuzer

Blood (2010) 116 (21): 1393.

https://doi.org/10.1182/blood.V116.21.1393.1393

Published: 2010

Journal Articles

Acute Myeloid Leukemia Cells Depend on VEGF, PDGFR and SCF Receptor Signaling: Leukemia Regression with Pazopanib.

Eric Gars, Christie S McGee, Raphael C Bosse, Elizabeth Wise, Amy Meacham, MS, Christopher R. Cogle, MD

Blood (2010) 116 (21): 1057.

https://doi.org/10.1182/blood.V116.21.1057.1057

Published: 2010

Journal Articles

Selective Targeting of Vascular Endothelial Growth Factor (VEGF) Receptor Signaling with Pazopanib and Vatalanib Induces Apoptosis in Chronic Lymphoctic Leukemia (CLL) Cells in Vitro Inhibits Growth of Human CLL Like Tumor Xenografts in Mice.

Julian Paesler, Iris Gehrke, Regina Razavi, Rajesh Kumar Gandhirajan, Alexandra Filipovich, Magdalena Hertweck, Felix Erdfelder, Sabrina Uhrmacher, Simon Jonas Poll-Wolbeck, Michael Hallek, MD, Karl Anton Kreuzer, MD

Blood (2009) 114 (22): 3451.

https://doi.org/10.1182/blood.V114.22.3451.3451

Published: 2009

Journal Articles

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)

H. Miles Prince, Dirk Hönemann, Andrew Spencer, David A. Rizzieri, Edward A. Stadtmauer, Andrew W. Roberts, Nizar Bahlis, Guido Tricot, Bill Bell, Douglas J. DeMarini, A. Benjamin Suttle, Katherine L. Baker, Lini N. Pandite

Blood (2009) 113 (19): 4819–4820.

https://doi.org/10.1182/blood-2009-02-207209

Published: 2009

Journal Articles

The Small-Molecule VEGF-Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma.

Klaus Podar, MD, MSc, PhD, Giovanni Tonon, MD, PhD, Martin Sattler, PhD, Yu-Tzu Tai, PhD, Steven LeGouill, MD, Hiroshi Yasui, MD, PhD, Kenji Ishitsuka, MD, PhD, Rakesh Kumar, PhD, Lini N. Pandite, MD, Teru Hideshima, MD, PhD, Dharminder Chauhan, PhD, Kenneth C. Anderson, MD

Blood (2006) 108 (11): 5003.

https://doi.org/10.1182/blood.V108.11.5003.5003

Published: 2006

NARROW

Concurrent Treatment of VEGFR Tyrosine Kinase Inhibitors (TKIs) and Factor Xa Inhibitors Is Associated with Increased Bleeding Risks

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Preclinical Evidence That Trametinib Enhances the Response to Tyrosine Kinase Inhibitors in Acute Myeloid Leukemia

The Impact of Chemotherapeutic Agents on Signaling and Epigenetics in Vascular Endothelial Cells

Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia Relapsing after Allogeneic Stem Cell Transplantation

Identification of Targeted Therapies for Rare Adult Mature T-Cell Leukemia Using Functional Ex Vivo Screening of Primary Patient Samples

Chemosensitizing Leukemia By Targeting the Leukemia Microenvironment with Vascular Disrupting Combretastatins

Development of a Clinically Relevant in Vitro Drug Screening Platform for Chemo-Refractory AML Patients

Activities Of Commonly Used Tyrosine Kinase Inhibitors Against Wild-Type C-KIT and Potential Impact On Normal Hematopoiesis

Differential Activity of Pazopanib and Imatinib Against PDGFRA-Related MPN and AML

The Receptor Tyrosine Kinase Inhibitors Vatalanib and Pazopanib Possess Strong Inhibitory Effect on Tumor Growth In a CLL-Like Xenograft Mouse Model

Acute Myeloid Leukemia Cells Depend on VEGF, PDGFR and SCF Receptor Signaling: Leukemia Regression with Pazopanib.

Selective Targeting of Vascular Endothelial Growth Factor (VEGF) Receptor Signaling with Pazopanib and Vatalanib Induces Apoptosis in Chronic Lymphoctic Leukemia (CLL) Cells in Vitro Inhibits Growth of Human CLL Like Tumor Xenografts in Mice.

Vascular endothelial growth factor inhibition is not an effective therapeutic strategy for relapsed or refractory multiple myeloma: a phase 2 study of pazopanib (GW786034)

The Small-Molecule VEGF-Receptor Inhibitor Pazopanib (GW786034B) Targets Both Tumor and Endothelial Cells in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only